SSY Group Gets Approval for New Paracetamol Variant in China; Variants Pass Consistency Eval

MT Newswires Live
2024-12-27

SSY Group (HKG:2005) obtained approval from China's National Medical Products Administration for the addition of a 0.5g specification to its Paracetamol tablets, a Friday bourse filing said.

The Chinese regulator has also approved both the 0.3g and 0.5g variants of the Paracetamol tablets as passing the consistency evaluation of the quality and efficacy of generic drugs.

The Paracetamol tablet is mainly used for fever caused by common cold or influenza, as well as for the relief of mild to moderate pain.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10